Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals Inc (ADIL) is a clinical-stage biopharmaceutical company pioneering personalized treatments for alcohol use disorder through advanced pharmacogenomics. This page provides investors and healthcare professionals with essential updates on ADIL's clinical trials, regulatory milestones, and strategic initiatives.
Access timely announcements about the company's lead investigational drug AD04—a serotonin-3 receptor antagonist designed for genetically identified patient groups. Stay informed about clinical study results, FDA communications, intellectual property developments, and partnership opportunities that demonstrate ADIL's progress in addiction medicine.
Key updates include progress reports on the 505(b)(2) regulatory pathway, companion diagnostic advancements, and peer-reviewed research publications. All content is curated to help stakeholders track the company's evidence-based approach to treating addictive disorders through precision medicine.
Bookmark this page for direct access to primary source materials and analysis-free reporting on ADIL's scientific and corporate developments. Check regularly for new filings, trial data disclosures, and strategic announcements that shape the company's trajectory in biopharmaceutical innovation.
Adial Pharmaceuticals has announced a transformative acquisition of Purnovate, a developer of non-opioid pain reduction therapies. This strategic move aims to diversify and expand Adial’s addiction-related pipeline, including its lead product AD04 for Alcohol Use Disorder, currently in Phase 3 trials. The acquisition is expected to enhance Adial’s drug portfolio and leverage Purnovate's expertise in adenosine analogs to tackle pain and addiction. However, successful completion is contingent on specific conditions, including a fair opinion from Adial’s financial advisor.
Adial Pharmaceuticals (NASDAQ:ADIL) issued a statement urging individuals struggling with substance use disorders to avoid driving under the influence, especially during the holiday season. CEO William Stilley emphasized the importance of understanding genetic factors in addiction treatment. The company is advancing its lead drug candidate, AD04, through clinical trials in seven countries, targeting Alcohol Use Disorder and potentially other addictions. A Phase 2b trial of AD04 demonstrated significant results in reducing drinking frequency and quantity without serious safety concerns.
Adial Pharmaceuticals has announced that its lead drug candidate, AD04, targeted for the treatment of Alcohol Use Disorder (AUD), was featured on the Local 12: Healthy Perspective news segment. This follows a prior feature on WKRC in Cincinnati, which has reached numerous media outlets nationwide. AD04 is currently being evaluated in a Phase 3 clinical trial and has demonstrated promising results, reducing the frequency and quantity of alcohol consumption with no significant safety concerns reported. The drug may also treat other addictive disorders.
Adial Pharmaceuticals (ADIL) reports that its lead drug candidate, AD04, for treating Alcohol Use Disorder (AUD), has gained exposure on multiple television news programs. The coverage highlights the potential of AD04 to help individuals control cravings. The company is currently conducting a Phase 3 clinical trial for AD04, which previously demonstrated promising results in reducing drinking frequency and severity without significant safety concerns. This media attention is expected to raise awareness about AUD, especially during the holiday season.
Adial Pharmaceuticals (NASDAQ:ADIL, ADILW) has signed a Common Stock Purchase Agreement with Keystone Capital Partners, allowing the sale of up to $15 million in common stock over time. The company, which has over $7 million in cash as of September 30, 2020, emphasizes that there are no immediate capital-raising plans. AD04, its lead drug for Alcohol Use Disorder, showed promise in clinical trials. The partnership aims to support future growth opportunities in the underserved addiction treatment market.
Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced progress in its ONWARD™ Phase 3 trial for AD04, targeting Alcohol Use Disorder (AUD). All 25 investigative sites are active, with over 25% of the patient enrollment completed. The enrollment rate has improved for four consecutive months, aiming for full enrollment by Q2 2021. Preliminary data reading is expected in Q4 2021. AD04 shows promising safety with no serious adverse events reported, and the potential market for AD04 in the U.S. is estimated to exceed $35 billion, addressing an urgent public health crisis exacerbated by COVID-19.
On October 22, 2020, Todos Medical and Adial Pharmaceuticals (NASDAQ:ADIL) announced a distribution agreement granting Todos non-exclusive sub-distribution rights to the Assure/FaStep® and EcoStep® COVID-19 antibody tests. The Assure/FaStep received FDA Emergency Use Authorization for fingerstick blood samples, expanding testing environments to various healthcare settings. CEO Gerald E. Commissiong emphasized the synergy in offering complementary COVID-19 tests. This agreement follows earlier sales of these tests, indicating client demand amid the ongoing pandemic.
Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced that the FDA has reactivated its Investigational New Drug (IND) application for AD04, a treatment for Alcohol Use Disorder (AUD). The IND was previously on clinical hold due to insufficient manufacturing data. This reactivation allows the company to pursue U.S. expedited review programs and initiate a planned Phase 1 pharmacokinetics study. The CEO noted the urgency of addressing the AUD crisis, exacerbated by the COVID-19 pandemic. Adial is also currently enrolling patients for its pivotal Phase 3 clinical trial in Europe.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced an initial firm order for 10,000 Assure/FaStep® COVID-19 IgG/IgM Rapid Test Devices from a California-based tech firm. The FaStep test is the first FDA-approved serology point-of-care test using fingerstick blood samples, crucial for rapid COVID-19 assessment. CEO William Stilley emphasized the importance of this testing in managing the virus's prevalence as the U.S. reopens. Adial has opened multiple sales channels to distribute the test devices, enhancing their market presence.
Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced the FDA's emergency use authorization (EUA) for its Assure/FaStep® COVID-19 IgG/IgM Rapid Test Device, the first point-of-care test using fingerstick blood samples. Previously, the test was restricted to venous blood samples. The EUA enables sales through iRemedy's network, tapping into a projected $3.52 billion market for rapid COVID-19 tests by year-end 2020. CEO William Stilley indicated this competitive advantage could boost adoption of their antibody tests to combat the COVID-19 pandemic.
